- 询价
- R&D
- 美国/中国
- xy-3610
- 2025年07月16日
- 科研使用
- Goat，Rabbit，Mouse
- 人，大鼠，小鼠，兔
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 形态：
液态/粉状
- 保存条件：
-20℃保存
- 克隆性：
多克隆
- 标记物：
见说明书
- 适应物种：
人，大鼠，小鼠，兔
- 宿主：
Goat，Rabbit，Mouse
- 应用范围：
科研使用
- 浓度：
1mg/1ml
- 靶点：
来电咨询
- BRST-1 (CU-18) Monoclonal Antibody (SIGNET)详细信息：
-
Description 
Monoclonal Antibody against BRST-1 (CU-18)
(Formerly Signet Catalog Nos: 610-01, 610-16 L1 Predilute, 610-26 L2 Predilute, 610-36 LV Predilute)Intended Use ** In Vitro Diagnostic (IVD) ** Clone CU-18 Form Tissue Culture Supernatant (in 0.01M PBS + 0.1% NaN3 + 1% BSA) Host Mouse Species Reactivity BRST-1 (CU-18) Monoclonal Antibody (SIGNET)Human IsoType IgG1 Specificity The BRST-1, clone CU-18, monoclonal antibody detects BCA-225, a 225kDa glycoprotein secreted by the T47D breast carcinoma cell line. Strong intracytoplasminc staining is seen in primary and metastatic breast carcinoma cell lines, primary and metastatic breast carcinoma tissue and cervical carcinomas.
This antibody was generated against a protein secreted by the T47D (Clone 11) human breast carcinoma cell line.
Concentrated Format:
SIG-3610-1000 [1 mL]
Prediluted Formats:
SIG-3610-16 [6 mL] is ready to use with Peroxidase Anti- Peroxidase detection systems.
SIG-3610-26 [6 mL] is ready-to-use with Biotin-based detection systems such as USA Ultra Streptavidin Detection (SIG-32250).
SIG-3610-36 [6 mL] is ready-to-use with Biotin based detection systems on Ventana ES and Ventana NexES automated immunostainers.Uses BRST-1 (CU-18) Monoclonal Antibody (SIGNET)This antibody is effective in immunohistochemistry (IHC). Suggested Working Dilution The optimal working dilution should be determined for each specific assay condition. - IHC: ≥1:40 (concentrated format) for Biotin based detection systems such as USA Ultra Streptavidin Detection (SIG-32250).
Tissue Sections: Formalin-fixed, paraffin-embedded tissues
Pretreatment: Not required
Incubation: 20 minutes at room temperature
Notes Positive tissue (human): Breast carcinoma Storage Store between 2-8°C. References Imam SA, et al. Comparison of two microwave based antigen retrieval solutions in unmasking epitopes in formalin-fixed tissue for immunostaining. Anticancer Res 15:1153-8, 1995.
Ansai S, et al. An immunohistochemical study of BCA-225 in various skin cancers. J Dermatol 21(1): 20-4, 1994.
Ma CK, et al. Comparative immunohistochemical study of primary and metastatic carcinomas of the liver. Am J Clin Pathol 99(5):551-7, 1993.Warranty/Conditions Covance products may not be resold or modified for resale without prior written approval. - IHC: ≥1:40 (concentrated format) for Biotin based detection systems such as USA Ultra Streptavidin Detection (SIG-32250).
- BRST-1 (CU-18) Monoclonal Antibody (SIGNET)
- xy-5482R phospho-MEF2C(Thr20)磷酸化肌细胞增强因子2C抗体
xy-10250R MMP13基质金属蛋白酶13抗体
xy-11525R MICAL1酪氨酸单氧化酶微管相关蛋白MICAL抗体
xy-11513R MKS1梅克尔-格鲁伯综合征相关蛋白抗体
xy-6811R MUM1突变的黑色素瘤相关抗原1抗体
xy-6816R MAGEA10黑色素瘤相关抗原10抗体
xy-6301R MAP3K2丝裂原活化蛋白激酶激酶2抗体
xy-6626R GPR24G蛋白偶联受体24抗体
xy-6722R MAPK organizer 1丝裂原活化蛋白激酶组织蛋白1抗体
xy-6680R MEIS1同源盒蛋白Meis1抗体
xy-6679R MAOA单氨氧化酶A抗体
xy-8512R MSX1MSH同源蛋白1样蛋白抗体
xy-9340R MARCH6膜相关环指蛋白6抗体
xy-5787R MMP19基质金属蛋白酶18/19
xy-5781R MIG7富含半胱氨酸蛋白质MIG7抗体
xy-5936R MOS原癌基因丝氨酸/苏氨酸蛋白激酶MOS抗体
xy-5792R MCPIP1单核细胞趋化诱导蛋白1抗体
xy-5885R Myosin heavy chain 1肌球蛋白重链抗体
xy-5876R MMP-28基质金属蛋白酶28抗体
xy-5875R MMP-23基质金属蛋白酶23抗体
xy-6551R MimitinMYC诱导线粒体蛋白抗体
xy-5879R MUC7粘蛋白7抗体
xy-5877R MUC13粘蛋白13抗体
xy-5878R MUC15粘蛋白15抗体
xy-5874R MMP-22基质金属蛋白酶22抗体
xy-6547R MAG1肺癌转移相关蛋白抗体
xy-6548R MARVELD1候选肿瘤抑制基因MARVELD1抗体
xy-6550R MTCP1成熟T淋巴细胞增殖蛋白1抗体
xy-6255R MAPK8IP1丝裂原活化蛋白激酶8相互作用蛋白1抗体
xy-4129R MYL6肌球蛋白轻链6抗体
xy-5479R phospho-MEF2C(Ser59)磷酸化肌细胞增强因子2C抗体
xy-5472R phospho-MCAM(Tyr641)磷酸化黑色素瘤细胞粘附分子CD146抗体
xy-4130R MEF2C肌细胞增强因子2C抗体
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
Technology and Production of Murine Monoclonal and Recombinant Antibodies and Antibody Fragments
production described by K�hler and Milstein in 1975 (1 ). In the last 30 yr a number of genetically engineered antibody constructions have emerged, including chimeric and human-like antibodies as well as different antibody fragments. Nowadays, 18 rnAb
In the field of therapeutic recombinant proteins, monoclonal antibodies (mAbs) have achieved a rising success with more than 30 mAbs that have reached the market in the past 20 years. From a structural standpoint, one of the most important
技术资料暂无技术资料 索取技术资料
